# A Phase I Study of HW241045 in Healthy Subjects

> **NCT07593690** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.** · enrollment: 102 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** HW241045 Formulation A
- **DRUG:** HW241045 Formulation B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07593690
- **Lead sponsor:** Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593690, "A Phase I Study of HW241045 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07593690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*